TOMI Secures Key Canadian Healthcare and Research Contracts
Event summary
- TOMI’s SteraMist iHP technology adopted by Canada’s largest health research organization for special pathogens unit.
- Successful deployments at a Nova Scotia trauma center and a research university in early 2026.
- Canadian distribution partner increased equipment inventory to support direct-to-customer sales across provinces.
- TOMI submitted competitive bids for potential purchases throughout the current fiscal year.
The big picture
TOMI’s expansion in Canada reflects a broader trend toward advanced, automated decontamination solutions in regulated healthcare and research environments. The company’s strategic wins in elite research laboratories and critical care hospitals position it as a key player in pathogen control, potentially setting a new standard for biosafety protocols. The investment in distribution infrastructure suggests a long-term commitment to the Canadian market, aligning with TOMI’s North American growth strategy.
What we're watching
- Market Penetration
- Whether TOMI can sustain its momentum in Canadian healthcare and research sectors through competitive bids and new customer acquisitions.
- Technology Adoption
- The pace at which SteraMist iHP becomes the standard for pathogen control in high-containment research and critical care environments.
- Operational Scaling
- How TOMI’s increased equipment inventory and distribution partner infrastructure will impact its ability to meet growing demand.
Related topics